All In Biotech

Drug Trial Radar · NCT04128163

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

A Twelve-month Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of QL1206 in Chinese Postmenopausal Women With Osteoporosis at High Risk of Fracture

Last checked: Nov 19, 2026Latest source record: Nov 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

440

Planned (sponsor's estimate)

Start

Jun 5, 2019

Primary completion

Aug 31, 2021

Study completion Dec 1, 2021

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial to compare the efficacy and safety of QL1206 and placebo in postmenopausal women with osteoporosis at high risk of fracture

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • QL1206Drug

    subcutaneous injection of 60 mg(60mg:1ml), Q6M, twice for one year. Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU

  • PlacebosDrug

    subcutaneous injection of(1ml), Q6M, twice for one year. Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine from Baseline up to 12 monthsTime frame: Baseline and Month 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai sixth people's hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.